This site is intended for healthcare professionals

European Commission (EC) Decision Reliance Procedure for determination of a MAA by MHRA.

Read time: 1 mins
Last updated:28th Jun 2021
Published:24th Apr 2021
MHRA Explanatory Note: For a period of two years from 1 January 2021, when determining an application for a Great Britain Marketing Authorisations (MA), the MHRA may rely on a decision taken by the European Commission (EC) on the approval of a new MA in the centralised procedure.Great Britain refers to England, Scotland and Wales.This route – the EC Decision Reliance Procedure (ECDRP) - is available to MAs approved via the centralised procedure.
Condition: Cardiovascular Events
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest